Key clinical trials of revefenacin, sponsored by Theravance Biopharma

Drug(s)	Indication	Phase	Status	Location(s)	Identifier
Revefenacin, placebo	Adults (aged > 40 years) with moderate to very severe COPD	III	Completed	USA	NCT02459080
Revefenacin, placebo	Adults (aged > 40 years) with moderate to very severe COPD	III	Completed	USA	NCT02512510
Revefenacin, tiotropium	Adults (aged > 40 years) with moderate to very severe COPD	III	Completed	USA	NCT02518139
Revefenacin, tiotropium	Adults (aged > 40 years) with moderate to very severe COPD and a low PIFR (< 60 L/min)	IIIb	Completed	USA	NCT03095456
Revefenacin, formoterol, placebo	Adults (aged > 40 years) with moderate to very severe COPD	IIIb	Completed	USA	NCT03573817
Revefenacin, placebo	Adults (aged 40–75 years) with moderate to severe COPD	II	Completed	USA	NCT02040792
Revefenacin, ipratropium, placebo	Adults (aged 40–75 years) with moderate to severe COPD	II	Completed	New Zealand, South Africa	NCT03064113; ANZCTR U1111-1120-8290
Revefenacin, placebo	Adults (aged 40–75 years) with moderate to severe COPD	II	Completed	United Kingdom, Northern Ireland and New Zealand	NCT01704404

COPD chronic obstructive pulmonary disease, PIFR peak inspiratory flow rate